Sentinel lymph node biopsy has no benefits for stage zero breast cancer

October 24, 2019

New Haven, Conn. -- Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.

The study, believed to be the first to examine the long-term impact of sentinel lymph node biopsies on thousands of older women, found that the procedure:However, the researchers found that the procedure increased the patient's risk for side-effects associated with the biopsy, which include pain, wound infection, and lymphedema, a painful condition that can restrict a woman's arm movements.

The findings are important because between 17% and 40% of women with DCIS currently undergo sentinel lymph node biopsies, even though experts do not recommend the procedure for DCIS patients, explains Shi-Yi Wang, M.D., a Yale School of Public Health associate professor and the study's lead author.

Approximately 25% of all breast cancer patients have DCIS, the earliest form of breast cancer, in which cancer cells invade the milk duct in the breast. Known as a "stage zero" breast cancer, DCIS is not life-threatening because it is non-invasive, meaning the cancer cells do not spread beyond the milk duct. If untreated, however, DCIS can develop into an invasive type of breast cancer.

Women diagnosed with DCIS almost always have surgery (usually a lumpectomy) to remove the DCIS and not the entire breast. Many also have the sentinel node biopsy, which involves removing a few lymph nodes under the arm to determine if the cancer has spread. Since DCIS is not invasive, experts do not recommend these biopsies for DCIS patients.

So why do so many women undergo sentinel lymph node biopsies?

"Proponents of sentinel lymph node biopsy cite concerns that occult microinvasive disease within the DCIS may not be detected via other methods. Also, the sentinel lymph node biopsy is included in the Centers for Medicare & Medicaid merit-based incentive payment system for invasive breast cancer," Wang said. "This might create a financial incentive for providers to perform these biopsies even for non-invasive conditions."

Wang's study compared the health outcomes of 5,957 women who had undergone a lumpectomy to remove DCIS, including 1,992 who had undergone a sentinel lymph node biopsy, with 3,965 women who did not have the biopsy procedure. The women, all between the ages of 67 and 94, were followed for a median of 5.75 years after their initial lumpectomy.

Wang cautioned that the findings may not be generalizable to young women and that more research is also needed to determine if sentinel lymph node biopsies benefit patients with a high-risk type of DCIS.

Laura Esserman, professor of surgery and radiology at the University of California-San Francisco and director of their Breast Care Clinic, is a DCIS researcher and said the findings have important implications for women with breast cancer.

"Some surgeons say that sentinel node biopsies are no big deal, but I disagree. All interventions have consequences," she said. "More is not better. More is just more, and in this case, more is worse." Esserman was not involved in the study.
The study is published in the journal JNCI Cancer Spectrum. The research was supported through a Patient-Centered Outcomes Research Institute (PCORI) Award [CER-1507-31631; 2016].

Contact: Fred Mamoun 203-536-4666 or & Michael Greenwood 203-737-5151 or

Yale University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to